Small Cell Lung Cancer News and Research RSS Feed - Small Cell Lung Cancer News and Research

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
Cancer experts to discuss novel treatment strategies at ESMO Asia 2016 Congress

Cancer experts to discuss novel treatment strategies at ESMO Asia 2016 Congress

The ESMO Asia 2016 Congress announces its press programme today. The meeting brings together cancer experts in Singapore, from 16 to 19 December 2016. [More]
Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Pembrolizumab was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen. [More]
Researchers focus on optimal use of immune agents in frontline setting for NSCLC treatment

Researchers focus on optimal use of immune agents in frontline setting for NSCLC treatment

Immunotherapy continues to revolutionize the field of non-small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting. [More]
HC-based NGS helps detect genomic alterations not identified in routine lung cancer screening

HC-based NGS helps detect genomic alterations not identified in routine lung cancer screening

The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes. [More]
Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab). [More]
Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials. [More]
Immunotherapy drug approved by FDA as first-line treatment for non-small cell lung cancer

Immunotherapy drug approved by FDA as first-line treatment for non-small cell lung cancer

Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC). [More]
Identification of new lung cancer subtypes could lead to personalized immunotherapies

Identification of new lung cancer subtypes could lead to personalized immunotherapies

Personalized therapies can potentially improve the outcomes of patients with lung cancer, but how to best design such an approach is not always clear. [More]
HIIT program effective in improving aerobic performances in early-stage operable NSCLC patients

HIIT program effective in improving aerobic performances in early-stage operable NSCLC patients

Preoperative high-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) improved aerobic performance in patients but failed to reduce early complications after tumor resection. [More]
Blood tests may decrease wait time between diagnosis and treatment of lung cancer

Blood tests may decrease wait time between diagnosis and treatment of lung cancer

A study from Gundersen Health System, La Crosse, Wisconsin, reveals to the value of blood-based genomic and proteomic testing in patients with lung cancer at the time of initial diagnoses. [More]
Study finds neoadjuvant immunotherapy safe, viable for early lung cancer patients before surgery

Study finds neoadjuvant immunotherapy safe, viable for early lung cancer patients before surgery

Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen. [More]
Single high-intensity SBRT dose can be effective in treating early stage NSCLC patients

Single high-intensity SBRT dose can be effective in treating early stage NSCLC patients

Stereotactic body radiation therapy (SBRT) is a specialized and highly targeted method of delivering radiotherapy, or radiation therapy, to treat cancer. [More]
Study helps identify optimal treatment option for NSCLC patients with brain metastases

Study helps identify optimal treatment option for NSCLC patients with brain metastases

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment. [More]
Increasing adoption of SBRT improves survival rates for older patients with early stage lung cancer

Increasing adoption of SBRT improves survival rates for older patients with early stage lung cancer

Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) rose from roughly 40 to 60 percent over the past decade, concurrent with the increasing adoption of SBRT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Increased use of SBRT linked to improved survival outcomes of NSCLC patients

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Yale researchers compare efficacy of four PD-L1 assay tests

Yale researchers compare efficacy of four PD-L1 assay tests

In a recent study, a Yale Cancer Center team compared the performance of the four available PD-L1 assay tests. [More]
Study compares survival outcomes of two recommended lung cancer staging strategies

Study compares survival outcomes of two recommended lung cancer staging strategies

In a study appearing in the September 13 issue of JAMA, Jouke T. Annema, M.D., Ph.D., of the Academic Medical Center, Amsterdam, and colleagues examined five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer. [More]
UNSW set to become home to world’s first pre-production prototype of high resolution microscope

UNSW set to become home to world’s first pre-production prototype of high resolution microscope

Cancer researchers in NSW will now have access to a range of cutting edge technology, including a world-first super-resolution microscope at UNSW, thanks a $4 million investment by the Cancer Institute NSW. [More]
Combinational analysis of FISH and IHC detects NSCLC patients with rare ALK fusions

Combinational analysis of FISH and IHC detects NSCLC patients with rare ALK fusions

The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment. [More]
Advertisement